These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10958598)

  • 21. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
    Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
    Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.
    Lilenbaum RC; Huber RM; Treat J; Masters G; Kaubitzsch S; Lane S; Wissel P
    Clin Lung Cancer; 2006 Sep; 8(2):130-4. PubMed ID: 17026814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
    Macdonald JS; Jacobson JL; Ketchel SJ; Weiss G; Taylor S; Mills G; Kuebler JP; Rivkin S; Conrad M
    Invest New Drugs; 2000 May; 18(2):199-202. PubMed ID: 10857998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
    von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
    J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
    Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
    Kadota RP; Stewart CF; Horn M; Kuttesch JF; Burger PC; Kepner JL; Kun LE; Friedman HS; Heideman RL
    J Neurooncol; 1999 May; 43(1):43-7. PubMed ID: 10448870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
    Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
    J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
    Garst J; Buller R; Lane S; Crawford J
    Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
    Scarfone G
    Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.
    Kraut EH; Balcerzak SP; Young D; Davis MP; Jacobs SA;
    Cancer Invest; 2002; 20(2):174-9. PubMed ID: 11901536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
    Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
    Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.